The Use of Nanomedicines for Site-Specific Delivery and Controlled Release
A special issue of Biomedicines (ISSN 2227-9059).
Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 405
Special Issue Editor
Special Issue Information
Dear Colleagues,
Nanomedicines have been employed for site-specific delivery and controlled release due to their ability to overcome many of the limitations of traditional drug-delivery techniques. The small size of nanoparticles (typically sub-200 nanometers) allows them to evade the body's immune system and target specific cells or tissues in the body. This makes them particularly useful for delivering drugs to difficult targets in the body, such as the brain or cancer cells. In recent years, nanotechnology has been adapted for controlled release of drugs over an extended period.
Nanoparticles can be engineered to have specific properties, such as surface charge and hydrophobicity, that allow them to interact with specific receptors on the surface of cells. This can enhance the targeting ability of the nanoparticles, making them more effective at delivering drugs to specific cells or tissues.
Additionally, nanoparticles can be designed to have a high drug loading capacity, which can help to increase the amount of drug that can be delivered to the target site. They also have the ability to protect the drug from degradation, thus increasing its bioavailability.
Overall, the use of nanomedicines in site-specific delivery and controlled release has the potential to improve the safety and efficacy of drugs as well as increase patient compliance and reduce side effects. This Special Issue seeks to collate recent key scientific research under nano-inspired drug-delivery research for various types of diseases.
Dr. Yaw Opoku-Damoah
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicines
- site-specific delivery
- controlled release
- nanoparticles
- bioavailability
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
